Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Clinical trial NCT04572451 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04572451
Sponsor: Yana Najjar
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Unresectable Solid Tumors Neoplasms Neoplasms by Histologic Type Neoplasms by Site Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Nivolumab

Start date: 2021-11-29
Primary completion: 2026-10-07
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.